RxMD signs drug development agreement with GlycoRegImmune

RxMD has collaborated with GlycoRegImmune (GRI) to develop new treatments by using GRI’s novel natural killer (NK) T cell targeted technologies for autoimmune, inflammatory and neurodegenerative conditions.

As per the terms of the agreement, RxMD will use its drug development expertise for enhancing GRI’s line of drugs.

GRI CEO Marc Hertz said they now have full access to RxMD’s drug development capabilities, which will allow them to design and execute development strategies for their drug candidates much more rapidly and efficiently.

RxMD CEO Sanjay Shukla said they look forward to collaborating with GRI to build a pipeline of new medicines for serious un- or under-treated conditions.